Monoclonal antibody | |
---|---|
Type | ? |
Target | Interleukin 6 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII | |
KEGG |
Ziltivekimab is a fully human monoclonal antibody against interleukin 6. It is developed by Novo Nordisk to treat heart failure. In clinical trials, levels of high-sensitivity C-reactive protein were reduced in people taking the drug.[1][2][3][4][5][6] The drug has also been tested in chronic kidney disease.[7]